E

    Enlivex Therapeutics Ltd (ENLV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.28
    -0.07 (-5.19%)

    Market Cap: $23.61M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(17/28)
    Avg Surprise
    -28.61%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$N/A$-0.02N/ABeat-
    Mar 26
    		$-0.15$-0.02-650.00%Miss+93.3%
    Dec 25
    		$-1.41$-0.45-213.33%Miss-513.0%
    Sep 25
    		$-1.35$-1.80+25.00%Beat+25.0%
    Jun 25
    		$-1.20$-2.40+50.00%Beat+50.0%
    Mar 25
    		$-2.25$-2.40+6.25%Beat+31.8%
    Dec 24
    		$-0.23$-0.16-43.75%Miss+96.8%
    Sep 24
    		$-1.80$-2.40+25.00%Beat+62.5%
    Jun 24
    		$-2.40$-1.20-100.00%Miss-500.0%
    Mar 24
    		$-3.30$-3.75+12.00%Beat+43.6%
    Dec 23
    		$-7.20$-4.20-71.43%Miss-23.1%
    Sep 23
    		$-4.80$-4.80+0.00%Beat-3.2%
    Jun 23
    		$-0.40$-0.46+13.04%Beat+95.1%
    Mar 23
    		$-5.85$-6.00+2.50%Beat+13.3%
    Dec 22
    		$-5.85$-5.70-2.63%Miss-105.3%
    Sep 22
    		$-4.65$-4.35-6.90%Miss-82.4%
    Jun 22
    		$-8.10$-6.75-20.00%Miss-184.2%
    Mar 22
    		$-6.75$-6.15-9.76%Miss-2600.0%
    Sep 21
    		$-2.85$-3.15+9.52%Beat-18.8%
    Jun 21
    		$-2.55$-3.90+34.62%Beat+26.1%
    Mar 21
    		$-2.85$-3.15+9.52%Beat-171.4%
    Dec 20
    		$-0.25$-0.24-4.17%Miss+0.0%
    Sep 20
    		$-2.40$-2.70+11.11%Beat-900.0%
    Jun 20
    		$-3.45$-3.60+4.17%Beat-2056.3%
    Mar 20
    		$-1.05N/A+70.83%Beat-556.3%
    Dec 19
    		$-0.25$-0.25+0.00%Beat-56.3%
    Sep 19
    		$-0.24N/AN/ABeat-100.0%
    Jun 19
    		$-0.16N/AN/ABeat+68.0%
    Mar 19
    		$-0.16N/AN/ABeat+93.2%
    Dec 18
    		$-0.16$0.00N/AMiss+0.0%
    Sep 18
    		$-0.12$0.00N/AMiss+95.3%
    Jun 18
    		$-0.50$0.00N/AMiss+87.5%
    Mar 18
    		$-2.34$0.00N/AMiss+63.4%
    Dec 17
    		$-0.16N/AN/ABeat+97.9%
    Sep 17
    		$-2.56$0.00N/ABeat+77.1%
    Jun 17
    		$-4.00$0.00N/ABeat-
    Mar 17
    		$-6.40$-11.60+44.83%Beat-
    Dec 16
    		$-7.60$-10.80+29.63%Beat-
    Sep 16
    		$-11.20$-8.80-27.27%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.02EV/EBITDA-1.49x
    Price/FCF-0.38xFCF Yield-261.71%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE126.20%ROIC-0.58%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio193.24xQuick Ratio193.24x
    Trading Statistics
    Beta1.47Avg Volume295.43K
    52-Week High$19.8052-Week Low$1.34

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.49
    SMA 20$1.69
    SMA 50$4.27
    SMA 200$11.53
    EMA 10$1.51
    EMA 20$1.96
    EMA 50$4.13
    EMA 200$10.06

    MACD

    Line: -0.79Signal: -0.96Hist: 0.18

    ADX

    ADX: 22.4+DI: 7.0-DI: 11.9

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$1.66

    Bollinger Bands

    Upper Band$2.23
    Lower Band$1.15
    %B Position6398%(Upper)
    Band Width0.12

    RSI (14-Day)

    Oversold
    17.6

    Momentum Oscillators

    Stoch %K8.0
    Stoch %D10.4
    Williams %R-87.4
    ROC (10d)-19.0%
    Momentum-0.30
    CCI (20d)-128.2
    MFI (14d)28.5

    Volatility Measures

    ATR (14d)$0.79(61.6%)
    StdDev (20d)0.27
    Hist Vol94.0%(High)

    Volume Flow

    VWAP$1.26
    OBV192.3M
    AD Line50.3B
    CMF (20d)-0.330

    Volume Metrics

    Avg Vol (20d)296.5K
    Vol Ratio1.3x
    VWMA (20d)$1.69

    Pivot Points

    R3$1.73
    R2$1.65
    R1$1.50
    Pivot Point$1.42
    S1$1.27
    S2$1.19
    S3$1.04

    Advanced Oscillators

    TSI-65.44
    Ultimate Osc34.6
    KST-533.04

    Financial Data

    QuarterDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$76,000$81,000$85,000$90,000$36,000$161,000$160,000$188,000$200,000$214,000$212,000$209,000
    Gross Profit$-76,000$-81,000$-85,000$-90,000$-36,000$-161,000$-160,000$-188,000$-200,000$-214,000$-212,000$-209,000
    Operating Expenses$5.79M$2.48M$2.99M$3.53M$5.63M$3.12M$2.99M$4.15M$5.89M$5.63M$6.65M$6.78M
    R&D$3.03M$1.48M$2.14M$2.55M$3.42M$2.35M$2.00M$2.86M$4.45M$4.35M$5.04M$5.18M
    SG&A$2.72M$1.07M$937,000$954,000$1.96M$771,000$987,000$1.09M$733,000$1.28M$1.61M$1.61M
    Operating Income$-5,861,000$-2,557,000$-3,078,000$-3,533,000$-5,632,000$-3,119,000$-2,986,000$-3,950,000$-6,091,000$-5,628,000$-6,649,000$-6,783,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$110,000$190,000$3.00M$335,000$143,000$435,000
    Income Before Tax$1.63B$-2,205,000$-1,868,000$-3,452,000$-5,176,000$-2,602,000$-3,096,000$-4,140,000$-9,095,000$-5,963,000$-6,792,000$-7,218,000
    Income Tax Expense$382.65M$0$0$0$0$0$0$144,724$156,188$253,586$89,915$435,000
    Net Income$1.24B$-2,205,000$-1,868,000$-3,452,000$-5,176,000$-2,602,000$-3,096,000$-4,140,000$-9,095,000$-5,963,000$-6,792,000$-7,218,000
    EBITDA$-5,785,000$-2,124,000$-2,993,000$-3,414,000$-5,140,000$-2,958,000$-2,826,000$-3,762,000$-5,891,000$-5,414,000$-6,437,000$-6,574,000
    EBIT$-5,861,000$-2,205,000$-3,078,000$-3,504,000$-5,176,000$-3,119,000$-2,986,000$-3,950,000$-6,091,000$-5,628,000$-6,649,000$-6,783,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ENLV

    News

    Enlivex Ltd expected to post a loss of 31 cents a share - Earnings Preview

    Enlivex Ltd is anticipated to report an earnings loss of 31 cents per share. This information comes from an earnings preview, and the full article is available through a subscription service on TradingView.

    TradingView•8/25/26•
    Bearish

    Enlivex Ltd. SEC Filing (Aug 14, 2026)

    This article reports on an SEC filing by Enlivex Ltd. (NASDAQ: ENLV) on August 14, 2026, which was a Notice of Effectiveness for an F-3 form. The filing was accepted by the SEC EDGAR system on the same day. The article also provides an overview of Enlivex Ltd.'s recent news and SEC filings.

    Stock Titan•8/14/26•
    Neutral

    Enlivex Ltd. (ENLV) sees 9.99% stake reported via convertible note

    Lind Global Asset Management XIV, LLC, The Lind Partners, LLC, and Jeff Easton have reported beneficial ownership of 9.99% of Enlivex Ltd.'s ordinary shares through a Senior Secured Convertible Promissory Note. The note includes a clause preventing conversion that would lead to ownership exceeding 9.99% of Enlivex's ordinary shares. Each reporting entity holds sole voting and dispositive power over 1,927,744 shares, representing this 9.99% stake.

    Stock Titan•8/13/26•
    Neutral

    Enlivex (ENLV) revises $21M secured convertible note, adds 10% interest trigger

    Enlivex Ltd. has amended its $21.0 million secured convertible promissory note with Lind Global Asset Management XIV, LLC. The amendment removes a market capitalization-related event of default and waives a previous default, while increasing the outstanding principal from $16.3 million to $19.2 million. A new provision adds a 10.0% annual interest rate if the company's market capitalization falls below $75.0 million.

    Stock Titan•8/11/26•
    Neutral

    Enlivex Therapeutics Ltd (ENLV) Earnings Forecast: Future EPS & Revenue Growth Estimates

    The article provides an earnings forecast for Enlivex Therapeutics Ltd (ENLV), highlighting its current earnings forecast score of 8.00 within the Biotechnology & Medical Research industry. Analysts project a target price of $7.00 for ENLV, with one analyst recommending a "Buy" rating. The report also details past and future EPS expectations, noting that the previous quarter's EPS was -$0.09 against an expectation of $167.84, and the next quarter's EPS is expected to be -$0.30.

    TradingKey•8/8/26•
    Bullish

    Frequently Asked Questions About ENLV

    Does ENLV pay dividends?
    Enlivex Therapeutics Ltd (ENLV) does not currently pay a regular dividend.
    What is ENLV's market cap?
    Enlivex Therapeutics Ltd (ENLV) has a market capitalization of $23.61M with a current stock price of $1.28.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In